ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
K. S. Konduri, R. Pattisapu, J. Pattisapu, G. G. Konduri, J. Zwetchkenbaum, B. Roy, M. Barman, A. Frazier, B. L. Hurst, N. Duzgunes
This paper shows ProLung-budesonide inhibits SARS-CoV-2 replication in vitro and reduces lung inflammation and airway hyperresponsiveness in mice.
bioRxiv · May 5, 2021 · PreprintPharmacology & Toxicology